Cancer Gene Profiling for Response Prediction.
Göttingen, Germany. In Methods Mol Biol, Dec 2015
Over the past few years, microarray technology has emerged as a central tool in addressing pertinent clinical questions, the answers to which are critical for the realization of a personalized genomic medicine, in which patients will be treated based on the biology of their tumor and their genetic profile (Quackenbush, N Engl J Med 354:2463-72, 2006; Jensen et al., Curr Opin Oncol 18:374-380, 2006; Bol and Ebner, Pharmacogenomics 7:227-235, 2006; Nevins and Potti, Nat Rev Genet 8:601-609, 2007).
[Genetic variants in C5 and poor response to eculizumab].
Ōsaka, Japan. In Rinsho Ketsueki, Jul 2015
This review summarizes the presentation entitled "Genetic variants in C5 and poor response to eculizumab" (N Engl J Med. 2014; 370: 632-639), given at Symposium 3 entitled "Basic and clinical topics on red blood cell membrane", during the 76th Annual Meeting of the Japanese Society of Hematology.
Redox proteomics: from bench to bedside.
Plattsburgh, United States. In Adv Exp Med Biol, 2013
These modifications include phosphorylation, glycosylation, S-nitrosylation, acetylation, lipidation, among others (Angew Chem Int Ed Engl 44(45):7342-7372, 2005).
Targeted treatments for symptom domains in child and adolescent autism.
New York City, United States. In Lancet, 2003
J McCracken and colleagues (N Engl J Med 2000; 347: 314-21) showed that the atypical antipsychotic risperidone reduced serious behavioural problems, such as tantrums, aggression, or self-injury in children with autism and in children with below-average intelligence quotients.